Companies: 10,795·Total market cap: $144.5T
Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc.

CTXRNASDAQHealthcare● Active
$0.59
+$0.00(+0.73%)
Market Cap$6632066
P/E Ratio
52W High$2.48
52W Low$0.476

Citius Pharmaceuticals, Inc. (CTXR) Revenue

Annual & quarterly revenue history · segment & region breakdown

CTXR · revenue · updated Jun 9, 2026

Core revenue metrics

Citius Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.01B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.01B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
1.16×
mktCap ÷ TTM rev
Revenue per day
$0M
Est. TTM ÷ 365
Revenue / employee
$244K
23 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Citius Pharmaceuticals, Inc. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
CTXR revenue by year · CTXR revenue history · CTXR annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Citius Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Citius Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Citius Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

CTXR revenue · 4 questions

CTXR's trailing twelve-month (TTM) revenue is $0.01B. That is an increase of 0.00% year-over-year from — in FY.

CTXR revenueCTXR annual revenuewhat is CTXR revenueCTXR TTM revenue

Source: FMP · Citius Pharmaceuticals, Inc. SEC filings · GAAP · Citius Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026